The impact of COVID-19 on familial Mediterranean fever: a nationwide study
Abstract The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 21 different centers. Demographics, FMF-related clinical and genetic characteristics, and COVID-19 outcomes were obtained. A total of 822 patients with FMF (mean age of 36 years) were included in the study. Fifty-nine of them (7%) had a COVID-19 diagnosis confirmed by real-time PCR test or chest CT findings. Most FMF patients with COVID-19 (58) had mild and moderate disease activity. All patients were on colchicine treatment. However, 8 of them (13.6%) were not compliant with colchicine use and 9 of them (15.3%) were colchicine resistant. Twelve FMF patients with COVID-19 were hospitalized. There were 4 patients requiring oxygen support. COVID-19 related complications were observed in 2 patients (1 thromboembolism, 1 acute respiratory distress syndrome). Hospitalized COVID-19 patients with FMF were older than non-hospitalized patients (median ages: 51 and 31 years, respectively; p: 0.002). Other FMF-related characteristics were similar between the groups. FMF-related characteristics were not found to be associated with poor outcomes in COVID-19. Thus, FMF may not be a risk factor for poor COVID-19 outcomes..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Rheumatology international - 41(2021), 8 vom: 25. Mai, Seite 1447-1455 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Günendi, Zafer [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
---|
doi: |
10.1007/s00296-021-04892-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2126374122 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2126374122 | ||
003 | DE-627 | ||
005 | 20230505114220.0 | ||
007 | tu | ||
008 | 230505s2021 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s00296-021-04892-6 |2 doi | |
035 | |a (DE-627)OLC2126374122 | ||
035 | |a (DE-He213)s00296-021-04892-6-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Günendi, Zafer |e verfasserin |0 (orcid)0000-0003-0966-0075 |4 aut | |
245 | 1 | 0 | |a The impact of COVID-19 on familial Mediterranean fever: a nationwide study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
520 | |a Abstract The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 21 different centers. Demographics, FMF-related clinical and genetic characteristics, and COVID-19 outcomes were obtained. A total of 822 patients with FMF (mean age of 36 years) were included in the study. Fifty-nine of them (7%) had a COVID-19 diagnosis confirmed by real-time PCR test or chest CT findings. Most FMF patients with COVID-19 (58) had mild and moderate disease activity. All patients were on colchicine treatment. However, 8 of them (13.6%) were not compliant with colchicine use and 9 of them (15.3%) were colchicine resistant. Twelve FMF patients with COVID-19 were hospitalized. There were 4 patients requiring oxygen support. COVID-19 related complications were observed in 2 patients (1 thromboembolism, 1 acute respiratory distress syndrome). Hospitalized COVID-19 patients with FMF were older than non-hospitalized patients (median ages: 51 and 31 years, respectively; p: 0.002). Other FMF-related characteristics were similar between the groups. FMF-related characteristics were not found to be associated with poor outcomes in COVID-19. Thus, FMF may not be a risk factor for poor COVID-19 outcomes. | ||
650 | 4 | |a COVID-19 | |
650 | 4 | |a Familial Mediterranean fever | |
650 | 4 | |a Rheumatic diseases | |
650 | 4 | |a Colchicine | |
650 | 4 | |a Hospitalization | |
650 | 4 | |a Poor outcomes | |
700 | 1 | |a Yurdakul, Fatma Gül |0 (orcid)0000-0001-8630-9233 |4 aut | |
700 | 1 | |a Bodur, Hatice |0 (orcid)0000-0003-3008-7007 |4 aut | |
700 | 1 | |a Cengiz, Ahmet Kıvanç |0 (orcid)0000-0002-4390-7169 |4 aut | |
700 | 1 | |a Uçar, Ülkü |0 (orcid)0000-0003-4838-1650 |4 aut | |
700 | 1 | |a Çay, Hasan Fatih |0 (orcid)0000-0001-5466-7482 |4 aut | |
700 | 1 | |a Şen, Nesrin |0 (orcid)0000-0003-0696-5834 |4 aut | |
700 | 1 | |a Keskin, Yaşar |0 (orcid)0000-0003-4457-5917 |4 aut | |
700 | 1 | |a Gürer, Gülcan |0 (orcid)0000-0001-8287-2264 |4 aut | |
700 | 1 | |a Melikoğlu, Meltem Alkan |0 (orcid)0000-0001-7519-9470 |4 aut | |
700 | 1 | |a Altıntaş, Duygu |0 (orcid)0000-0003-4558-0478 |4 aut | |
700 | 1 | |a Deveci, Hülya |0 (orcid)0000-0001-7491-1569 |4 aut | |
700 | 1 | |a Baykul, Merve |0 (orcid)0000-0003-0434-396X |4 aut | |
700 | 1 | |a Nas, Kemal |0 (orcid)0000-0002-5845-0851 |4 aut | |
700 | 1 | |a Çevik, Remzi |0 (orcid)0000-0002-4124-1586 |4 aut | |
700 | 1 | |a Karahan, Ali Yavuz |0 (orcid)0000-0001-8142-913X |4 aut | |
700 | 1 | |a Toprak, Murat |0 (orcid)0000-0002-6490-4645 |4 aut | |
700 | 1 | |a Ketenci, Sertaç |0 (orcid)0000-0002-2950-8778 |4 aut | |
700 | 1 | |a Nayimoğlu, Mehmet |0 (orcid)0000-0003-2760-8406 |4 aut | |
700 | 1 | |a Sezer, İlhan |0 (orcid)0000-0003-1324-2108 |4 aut | |
700 | 1 | |a Demir, Ali Nail |0 (orcid)0000-0001-5713-4120 |4 aut | |
700 | 1 | |a Ecesoy, Hilal |0 (orcid)0000-0001-9274-168X |4 aut | |
700 | 1 | |a Duruöz, Mehmet Tuncay |0 (orcid)0000-0003-3584-2788 |4 aut | |
700 | 1 | |a Yurdakul, Ozan Volkan |0 (orcid)0000-0003-4567-8133 |4 aut | |
700 | 1 | |a Sarıfakıoğlu, Ayşe Banu |0 (orcid)0000-0002-2819-3233 |4 aut | |
700 | 1 | |a Ataman, Şebnem |0 (orcid)0000-0003-3570-3825 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Springer Berlin Heidelberg, 1981 |g 41(2021), 8 vom: 25. Mai, Seite 1447-1455 |w (DE-627)129098183 |w (DE-600)8286-7 |w (DE-576)014434903 |x 0172-8172 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2021 |g number:8 |g day:25 |g month:05 |g pages:1447-1455 |
856 | 4 | 1 | |u https://doi.org/10.1007/s00296-021-04892-6 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
951 | |a AR | ||
952 | |d 41 |j 2021 |e 8 |b 25 |c 05 |h 1447-1455 |